Literature DB >> 27670867

Expected and perceived efficacy of complementary and alternative medicine: A comparison views of patients with cancer and oncologists.

Sang Hyuck Kim1, Dong Wook Shin2, You-Seon Nam3, So Young Kim4, Hyung-Kook Yang5, Be Long Cho6, Keeho Park7, Heui-Sug Jo8, Chang-Yeol Yim9, Sin Kam10, Jong-Hyock Park11.   

Abstract

BACKGROUND & AIMS: This study sought to identify discrepancies between the expectations of patients with cancer and oncologists regarding the efficacy of complementary and alternative medicines (CAMs), and to determine how patients evaluate CAM efficacy after its use.
METHODS: Data from the Cancer Patient Experience Study, a nationwide survey, were used. Seven subdivided efficacy domains were included in the survey. An oncologist-patient matching analysis was done to assess the concordance of CAM efficacies between oncologists and patients with cancer. In addition, the patients' expectations of CAM efficacies were compared before and after use.
RESULTS: Out of 719 participants, 201 patients with cancer (28.0%) reported using CAMs. The patients with cancer generally tended to be more positive about CAM efficacies than the oncologists. The largest discrepancy in efficacy perception was found in the efficacy domain of survival benefit, which included complete disease remission and prolonged survival. Many patients reported that they did not experience the positive efficacy they had anticipated before use. However, a substantial proportion of patients indicated that CAMs were as effective as they had expected, even though there is little evidence supporting the CAM efficacies.
CONCLUSIONS: There was a marked discrepancy and a lack of concordance in expectations of CAM efficacy between patients with cancer and oncologists. Better communication between the patients and oncologists regarding CAM efficacy would be needed to make the patients to have shared expectations, and to reduce unnecessary CAM use.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer patient; Complementary and alternative medicine; Discrepancy; Efficacy; Oncologist

Mesh:

Year:  2016        PMID: 27670867     DOI: 10.1016/j.ctim.2016.07.005

Source DB:  PubMed          Journal:  Complement Ther Med        ISSN: 0965-2299            Impact factor:   2.446


  6 in total

1.  Correlation between an integrative oncology treatment program and survival in patients with advanced gynecological cancer.

Authors:  Yakir Segev; Ofer Lavie; Nili Stein; Walid Saliba; Noah Samuels; Eiman Shalabna; Orit Gressel Raz; Elad Schiff; Eran Ben-Arye
Journal:  Support Care Cancer       Date:  2021-01-06       Impact factor: 3.603

Review 2.  Unproven Therapies for Diabetes and Their Implications.

Authors:  Jothydev Kesavadev; Banshi Saboo; Shaukat Sadikot; Ashok Kumar Das; Shashank Joshi; Rajeev Chawla; Hemant Thacker; Arun Shankar; Lakshmy Ramachandran; Sanjay Kalra
Journal:  Adv Ther       Date:  2016-11-18       Impact factor: 3.845

3.  Use of Complementary Traditional Chinese Medicines by Adult Cancer Patients in Taiwan: A Nationwide Population-Based Study.

Authors:  Yi-Ting Kuo; Tung-Ti Chang; Chih-Hsin Muo; Mei-Yao Wu; Mao-Feng Sun; Chia-Chou Yeh; Hung-Rong Yen
Journal:  Integr Cancer Ther       Date:  2017-06-30       Impact factor: 3.279

4.  Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients.

Authors:  Joon Young Choi; Wonjun Ji; Chang-Min Choi; Chaeuk Chung; Jae Myoung Noh; Cheol-Kyu Park; In-Jae Oh; Hong In Yoon; Hyeong Ryul Kim; Ho Young Kim; Chang Dong Yeo; Seung Hun Jang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2020-12-08

5.  Risks and benefits of antioxidant dietary supplement use during cancer treatment: protocol for a scoping review.

Authors:  L Susan Wieland; Ilana Moffet; Sydney Shade; Ashkan Emadi; Cheryl Knott; Emily F Gorman; Christopher D'Adamo
Journal:  BMJ Open       Date:  2021-04-13       Impact factor: 2.692

6.  The Current Status of Integrative Oncology in Korea.

Authors:  Eun-Bin Kwag; Soo-Dam Kim; Ji Hye Park; So-Jung Park; Mi-Kyung Jeong; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.